340B Court Decision Threatens To Expand Patient Eligibility; Can Pharmacy Restrictions Counter Program Growth?
Court ruling in litigation brought against the US government by Genesis Healthcare may elicit competing reactions among stakeholders but is expected to stir up the 340B market.
You may also be interested in...
Health policy experts and biopharma supply chain stakeholders discuss prospects for legislation reforming the Inflation Reduction Act, pharmacy benefit manager practices, and the 340B program during a recent conference.
Stakeholders differ on whether the rapid growth in spending is to be expected, given the realities in health care and specialty drug costs, or that the data underscores the need for oversight and reform of the 340B program.
Third Circuit is first of three federal appeals courts to issue a decision in multiple lawsuits over drug companies’ 340B contract pharmacy restrictions, which have led to conflicting lower court rulings on whether such restrictions are unlawful.